Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche nears completion of Memory acqusition

This article was originally published in Scrip

Executive Summary

Roche's wholly owned subsidiary 900 North Point Acquisition Corporation has accepted all shares validly tendered and not withdrawn pursuant to its tender offer for all outstanding shares of Memory Pharmaceuticals' common stock at $0.61 per share in cash. Around 73,169,195 shares of Memory's common stock were tendered in the offer and not withdrawn, representing approximately 89% of Memory's outstanding shares. Roche now intends to complete the acquisition through a merger as soon as practicable.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts